OTS have already identified a number of cancer-specific-genes that would be applicable for development of molecular-targeted anti-cancer therapies. OTS has been pursuing the medicinal discovery research with understanding the subcellular localization, mode of function, and immunogenicity of the target cancer-specific-genes.
- Investor Relations31/08/2017The announcement of the initiation of a Phase I/II clinical study for OTS167 in patients with refractory or relapsed leukemia at Weill Cornell Medicine
- Investor Relations15/08/2017The first-patient enrollment in Phase I clinical study of OTS167, MELK specific inhibitor, for breast cancer patients
- Investor Relations10/08/2017Patent Registration for MELK-specific inhibitors in European Patent Office
Our service offers comprehensive analysis of TCR repertoire from blood and tissue samples using next generation sequencing technology. A detailed data analysis will be performed. We ensure that we will perform this service consistently, from sample preparation to delivering results.
and Safer Cancer Treatments
Pursuing “To develop anti-cancer medicine and anti-cancer therapy with high efficacy and minimum risk of adverse events, and to win the war against cancer”, OTS has been conducting research and development, by collaborating with Professor Yusuke Nakamura, a genomics pioneer.